medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2014, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2014; 30 (2)

AML1-ETO fusion gen: characteristics in acute myeloid leukemia

Garrote SH, Amor VAM, Díaz AC, Suárez GY, Gómez PM

Language: Spanish
References: 23
Page: 98-107
PDF size: 52.97 Kb.


ABSTRACT

Acute myeloid leukemia (AML) is a heterogeneous bone marrow malignancy where patients with the cytogenetic t(8;21) abnormality represent a subset with specific clinical and biological characteristics. The translocation results in an in-frame fusion of two genes, resulting in a fusion protein of one N-terminal domain from the AML1 gene and four C-terminal domains from the ETO gene. This protein has multiple effects on the regulation of the proliferation, the differentiation and the viability of leukemic cells. The translocation can be detected as the only genetic abnormality or as part of more complex abnormalities. In contrast to other AML patients, the diagnosis of t(8;21) AML can be made even when less than 20 % leukemic blasts are present in the bone marrow. The leukemic cells show specific global gene expression and microRNA profiles; and usually there is a low risk of leukemia relapse after high-dose cytarabine therapy.


REFERENCES

  1. Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud O. Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications. J Biomed Biotechnol. 2011 [acceso: 12 de agosto de 2013];2011. Disponible en: http://dx.doi.org/10.1155/2011/104631

  2. Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT. Acute Myelogenous Leukemia. In: William´s Hematology. 8th ed. New York: McGraw-Hill. 2010.

  3. Thompson MA. Molecular Genetics of Acute Leukemia. In: Wintrobe's Clinical Hematology. 12th Ed. Philadelphia: Lippincott Williams & Wilkins. 2009.

  4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51.

  5. Yan M, Ahn EY, Hiebert SW, Zhang DE. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood. 2009 Jan 22;113(4):883-6.

  6. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia. 2012 Aug;26(8):1829-41.

  7. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H et al. Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1-ETO Translocation. Molecular and cellular biology, Aug. 2002;22(115):5506-17.

  8. GoyalM ,Gayathri K. Diagnostic Approach In Acute Myeloid Leukemias In Line With Who 2008 Classification. In: Koschmieder S, Editor. Myeloid Leukemia-Clinical Diagnosis and Treatment; 2011. p. 157-96.

  9. Foran JM. New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic. Hematology Am Soc Hematol Educ Program. 2010;2010:47-55.

  10. Owen C J, Fitzgibbon J. The genetics of acute myeloid leukemias. In: Molecular Hematology. 3rd ed. London: Wiley-Blackwell. 2010. p. 42-50.

  11. Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. Cancer Res. 2010 May 15;70(10):3985-95.

  12. Lin P, Medeiros LJ. Molecular Genetic Abnormalities in Acute and Chronic Leukemias. In: Molecular diagnostics for the clinical laboratorian. 2da ed. New Jersey: Human Press. 2006. p. 415-36.

  13. Kwok C, Zeisig BB, Qiu J, Dong S, So CW. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homooligomeric complexes. Proc Natl Acad Sci USA. 2009 Feb;106(8):2853-8.

  14. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. NatMed. 2006 Aug;12(8):945-9.

  15. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML, "Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia onsurvival, "Am J Clin Pathol. 2003 May;119(5):672-80.

  16. Sazawal S, Kumar B, HasanSk, Dutta P, Kumar R, Chaubey R et al. Haematological & molecular profile of acute myelogenous leukaemia in India. Indian J Med Res. March 2009;129:256-61.

  17. Mrózek K, Bloomfield CD. "Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr. 2008;39:52-7.

  18. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007 Feb;21(2):340-50.

  19. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012 Mar 22;366(12):1079-89.

  20. Shin HJ, Chung J, Kim HJ, Sohn SK, MinYH, Won JH et al. Bone marrow cellularity is a single most important independent prognostic factor in AML patients with t(8;21). ASH Annual Meeting Abstracts. 2010. Disponible en: https://ash.confex.com/ash/2010/webprogram/Paper32555.html [Acceso: 12 de agosto de 2013].

  21. Jongen-Lavrencic M, Sun SU, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111(10):5078-85.

  22. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations". Proc Natl AcadSci USA. 2008 Oct 7;105(40):15535-40. doi: 10.1073/pnas.0808266105.

  23. Licciulli S, Cambiaghi V, Scafetta G, Gruszka AM. Pirindownregulation is a feature of AML and leads to impairment of terminal myeloid differentiation. Leukemia. 2010 Feb;24(2):429-37.




2020     |     www.medigraphic.com